GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Additional Paid-In Capital

Cyclacel Pharmaceuticals (STU:UXI) Additional Paid-In Capital : €395.53 Mil(As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cyclacel Pharmaceuticals Additional Paid-In Capital?


Cyclacel Pharmaceuticals's quarterly additional paid-in capital declined from Sep. 2023 (€401.47 Mil) to Dec. 2023 (€394.12 Mil) but then increased from Dec. 2023 (€394.12 Mil) to Mar. 2024 (€395.53 Mil).

Cyclacel Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (€374.32 Mil) to Dec. 2022 (€399.29 Mil) but then declined from Dec. 2022 (€399.29 Mil) to Dec. 2023 (€394.12 Mil).

Cyclacel Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Additional Paid-In Capital Chart

Cyclacel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 333.13 328.86 374.32 399.29 394.12

Cyclacel Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 395.39 391.01 401.47 394.12 395.53

Cyclacel Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Cyclacel Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals (STU:UXI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Additional Paid-In Capital
Comparable Companies
REVB BTAX TSOI CPMV APVO AXIM EIGRQ FNCH SEEL ACUT OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
CYCCP.PFD:USA CYCC:USA
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Website
https://www.cyclacel.com
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals (STU:UXI) Headlines

No Headlines